asurgeryАмбулаторная хирургияAmbulatornaya khirurgiya = Ambulatory Surgery (Russia)2712-87412782-2591ООО «ГРУППА РЕМЕДИУМ»asurgery-91Research ArticleОРТОПЕДИЯORTHOPEDICSНизкомолекулярный гепарин Цибор: опыт применения в хирургической практикеLow molecular weight heparin zibor: experience of administration in surgical practiceКудыкинМ. Н.KudykinM. N.noemail@neicon.ruПриволжский федеральный медицинский исследовательский центрРоссияVice-President of Russian Association of PhlebologistsRussian Federation20173012201703-46067Copyright © Кудыкин М.Н., 20172017Кудыкин М.Н.Kudykin M.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.a-surgeon.ru/jour/article/view/91

Венозные тромбозы и связанные с ними эмболические осложнения (венозные тромбоэмболические осложнения - ВТЭО) продолжают оставаться одними из самых опасных осложнений периоперационного периода у больных хирургического профиля. Тромбоэмболия легочных артерий (ТЭЛА), по данным современных эпидемиологических исследований, достигает более чем 1 случая на 1000 оперативных пособий.

Venous thromboses and associated embolic complications (venous thromboembolic complications (VTEC)) remain the most dangerous complications of the perioperative period in patients with surgical profile. According to modern epidemiological studies, the incidence of pulmonary artery thromboembolia (PATE) reaches more than 1 case per 1,000 surgical interventions.

венозные тромбозыхирургические вмешательствавенозные тромбоэмболические осложненияпрофилактикаvenous thrombosissurgical interventionsvenous thromboembolic complicationspreventionReferencesBagLin T. Venous thromboembolism in hospitalised patients: a public health crisis. Br J Haematol, 2008, 141(6): 764-770.BagLin T. Venous thromboembolism in hospitalised patients: a public health crisis. Br J Haematol, 2008, 141(6): 764-770.Cohen AT, Agnelli G, Anderson FA et aL. Venous thromboembolism (VTE) in Europe. Thromb Haemost, 2007, 98(4): 756-764.Cohen AT, Agnelli G, Anderson FA et aL. Venous thromboembolism (VTE) in Europe. Thromb Haemost, 2007, 98(4): 756-764.Khan MI, O'Leary C, Silvan V, O'Brien A, O'Connor M, Duggan C, O'Shea Venous Thromboembolism - Risk Assessment Tool and Thromboprophylaxis Policy: A National Survey. S. Ir Med J., 2017 Jan 11, 110(1): 499.Khan MI, O'Leary C, Silvan V, O'Brien A, O'Connor M, Duggan C, O'Shea Venous Thromboembolism - Risk Assessment Tool and Thromboprophylaxis Policy: A National Survey. S. Ir Med J., 2017 Jan 11, 110(1): 499.SchuLman S, Ageno W, Konstantinides SV. Venous thromboembolism: Past, present and future. Thromb Haemost, 2017 Jun 28, 117(7): 1219-1229.SchuLman S, Ageno W, Konstantinides SV. Venous thromboembolism: Past, present and future. Thromb Haemost, 2017 Jun 28, 117(7): 1219-1229.Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология, 2010, 1: 2-37.Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология, 2010, 1: 2-37.Geerts WH, Heit JA, CLagett GP et aL. Prevention of venous thromboembolism. Chest, 2001, 119 (suppL. 1): 132-75.Geerts WH, Heit JA, CLagett GP et aL. Prevention of venous thromboembolism. Chest, 2001, 119 (suppL. 1): 132-75.Nakamura M, Yamada N, Ito M. Novel Anticoagulant Therapy of Venous Thromboembolism: Current Status and Future Directions. Ann Vasc Dis, 2017 Jun 25, 10(2): 92-98.Nakamura M, Yamada N, Ito M. Novel Anticoagulant Therapy of Venous Thromboembolism: Current Status and Future Directions. Ann Vasc Dis, 2017 Jun 25, 10(2): 92-98.Kearon C, AkL EA, Comerota AJ et aL. Antithrombotic therapy for venous thromboembolic disease: antithrombotic therapy and prevention of thrombosis. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition). Chest, 2012, 141: e419S-e494S.Kearon C, AkL EA, Comerota AJ et aL. Antithrombotic therapy for venous thromboembolic disease: antithrombotic therapy and prevention of thrombosis. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition). Chest, 2012, 141: e419S-e494S.Guidelines o the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Eur Heart J, 2008, 29: 2276-2315.Guidelines o the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Eur Heart J, 2008, 29: 2276-2315.FaLkon L, Saenz-Campos D, Antonijoan R, Martin S, Barbanoj M, Fontcuberta J. Bioavailability and pharmacokinetics of a new Low molecular weight heparin (RO-11). A three way cross-over study in healthy volunteers. Thromb. Res., 1995, 78: 77-86.FaLkon L, Saenz-Campos D, Antonijoan R, Martin S, Barbanoj M, Fontcuberta J. Bioavailability and pharmacokinetics of a new Low molecular weight heparin (RO-11). A three way cross-over study in healthy volunteers. Thromb. Res., 1995, 78: 77-86.BorreLL M, Antonijoan RM, Ortin R et aL. Pharmacokinetic profiles of two LMWH: Bemiparin 3,500 IU and Enoxaparin 4,000 IU after subcutaneous administration in heaLthy voLunteers. Thromb. Haemost., 2001, 86(SuppL.): CD3578.BorreLL M, Antonijoan RM, Ortin R et aL. Pharmacokinetic profiles of two LMWH: Bemiparin 3,500 IU and Enoxaparin 4,000 IU after subcutaneous administration in heaLthy voLunteers. Thromb. Haemost., 2001, 86(SuppL.): CD3578.FaLkon L, Saenz-Campos D, Antonijoan R, Martin S, Barbanoj M, Fontcuberta J. BioavaiLabiLity and pharmacokinetics of a new Low moLecuLar weight heparin (RO-11). A three way cross-over study in heaLthy voLunteers. Thromb. Res., 1995, 78: 77-86.FaLkon L, Saenz-Campos D, Antonijoan R, Martin S, Barbanoj M, Fontcuberta J. BioavaiLabiLity and pharmacokinetics of a new Low moLecuLar weight heparin (RO-11). A three way cross-over study in heaLthy voLunteers. Thromb. Res., 1995, 78: 77-86.FaLkon L, Bayes M, Frontera G, Gari M, Barbanoj M, Fontcuberta J. Pharmacokinetics and toLerabiLity of a new Low moLecuLar mass heparin (RO-11) in healthy volunteers - a dose-finding study within the therapeutical range. Thromb. Haemost., 1997, 77: 133-136.FaLkon L, Bayes M, Frontera G, Gari M, Barbanoj M, Fontcuberta J. Pharmacokinetics and toLerabiLity of a new Low moLecuLar mass heparin (RO-11) in healthy volunteers - a dose-finding study within the therapeutical range. Thromb. Haemost., 1997, 77: 133-136.Abbas MS. Bemiparin versus Enoxaparin in the Prevention of Venous Thromboembolism among Intensive Care Unit Patients. Indian J Crit Care Med, 2017 Jul, 21(7):419-423.Abbas MS. Bemiparin versus Enoxaparin in the Prevention of Venous Thromboembolism among Intensive Care Unit Patients. Indian J Crit Care Med, 2017 Jul, 21(7):419-423.Coltignon F, Frydman A, Capiain H et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin, nadroparin - administered subcuta-neously in heathy volunteers (doses for prevention of thromboembolism). Thromb. Haemost., 1995, 73: 630-640.Coltignon F, Frydman A, Capiain H et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin, nadroparin - administered subcuta-neously in heathy volunteers (doses for prevention of thromboembolism). Thromb. Haemost., 1995, 73: 630-640.Qureshi W, Ali Z, Amjad W, Alirhayim Z, Farooq H, Qadir S, Khalid F, Al-Mallah MH. Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants. Front Cardiovasc Med, 2016 Jul 28, 3: 24.Qureshi W, Ali Z, Amjad W, Alirhayim Z, Farooq H, Qadir S, Khalid F, Al-Mallah MH. Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants. Front Cardiovasc Med, 2016 Jul 28, 3: 24.Moreno Gonzalez E., Fontcuberta J., De La Llama F. Prophylaxis of thromboembolic disease with RO-11 (ROVI), during abdominal surgery. Hepatogastroenterology, 1996, 43: 744-747.Moreno Gonzalez E., Fontcuberta J., De La Llama F. Prophylaxis of thromboembolic disease with RO-11 (ROVI), during abdominal surgery. Hepatogastroenterology, 1996, 43: 744-747.Kakkar W, Howes J, Sharma V, Kadziola Z. A comparative, double-blind, randomized trial of a new-second generation LMWH (Bemiparin) and UFH in the prevention of post-operative venous thromboembolism in patients undergoing hip arthroplasty. Thromb. Haemost., 2000, 83: 523-529.Kakkar W, Howes J, Sharma V, Kadziola Z. A comparative, double-blind, randomized trial of a new-second generation LMWH (Bemiparin) and UFH in the prevention of post-operative venous thromboembolism in patients undergoing hip arthroplasty. Thromb. Haemost., 2000, 83: 523-529.Abad JI, Gomez-Outes A, Martinez-Gonzalez J, Rocha E. A prospective observational study on the effectiveness and safety of be- miparin, first dose administered 6 h after knee or hip replacement surgery. Arch Orthop Trauma Surg, 2007 Oct, 127(8): 665-670.Abad JI, Gomez-Outes A, Martinez-Gonzalez J, Rocha E. A prospective observational study on the effectiveness and safety of be- miparin, first dose administered 6 h after knee or hip replacement surgery. Arch Orthop Trauma Surg, 2007 Oct, 127(8): 665-670.Navarro-Quilis A, Castellet E, Rocha E, Paz-Jimenez J, Planes A. Efficacy and safety of bemiparin compared with Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty. A randomized double-blind clinical trial. J. Thromb. Haemost., 2003, 1: 425-432.Navarro-Quilis A, Castellet E, Rocha E, Paz-Jimenez J, Planes A. Efficacy and safety of bemiparin compared with Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty. A randomized double-blind clinical trial. J. Thromb. Haemost., 2003, 1: 425-432.Vavken P, Lunzer A, Grohs JG. A prospective cohort study on the effectiveness of 3500 IU versus 5000 IU bemiparin in the prophylaxis of postoperative thrombotic events in obese patients undergoing orthopedic surgery. Wien Klin Wochenschr, 2009, 121(13-14): 454-458.Vavken P, Lunzer A, Grohs JG. A prospective cohort study on the effectiveness of 3500 IU versus 5000 IU bemiparin in the prophylaxis of postoperative thrombotic events in obese patients undergoing orthopedic surgery. Wien Klin Wochenschr, 2009, 121(13-14): 454-458.Rodriguez-Manas L., Gomez-Huelgas R, Veiga-Fernandez F, Ruiz GM, Gonzalez JM Thromboprophylaxis with the low-molecular-weight heparin bemiparin sodium in elderly medical patients in usual clinical practi-ce: the ANCIANOS study. Clin DrugInvestig, 2010, 30(5): 337-345.Rodriguez-Manas L., Gomez-Huelgas R, Veiga-Fernandez F, Ruiz GM, Gonzalez JM Thromboprophylaxis with the low-molecular-weight heparin bemiparin sodium in elderly medical patients in usual clinical practi-ce: the ANCIANOS study. Clin DrugInvestig, 2010, 30(5): 337-345.Balibrea JL, Altimiras J, Larruzea I, Gomez-Outes A, Martinez-Gonzalez J, Rocha E. Optimal dosing of bemiparin as prophylaxis aga-inst venous thromboembolism in surgery for cancer: an audit of practi-ce. Int J Surg, 2007 Apr, 5(2): 114-119.Balibrea JL, Altimiras J, Larruzea I, Gomez-Outes A, Martinez-Gonzalez J, Rocha E. Optimal dosing of bemiparin as prophylaxis aga-inst venous thromboembolism in surgery for cancer: an audit of practi-ce. Int J Surg, 2007 Apr, 5(2): 114-119.Kakkar W, Balibrea JL, Martinez-Gonzalez J, Prandoni P. Ex-tended prophylaxis with bemiparin for the prevention of venous throm-boembolism after abdominal or pelvic surgery for cancer: the CANBE- SURE randomized study. J Thromb Haemost,2010 Jun, 8(6): 1223-1229.Kakkar W, Balibrea JL, Martinez-Gonzalez J, Prandoni P. Ex-tended prophylaxis with bemiparin for the prevention of venous throm-boembolism after abdominal or pelvic surgery for cancer: the CANBE- SURE randomized study. J Thromb Haemost,2010 Jun, 8(6): 1223-1229.Kakkar W, Gebska M, Kadziola Z, Saba N, Carrasco P. Lowmolecular weight heparin in the acute and long-term treatment of deep- vein-thrombosis. Thromb. Haemost., 2003, 89: 674-680.Kakkar W, Gebska M, Kadziola Z, Saba N, Carrasco P. Lowmolecular weight heparin in the acute and long-term treatment of deep- vein-thrombosis. Thromb. Haemost., 2003, 89: 674-680.Santamaria A, Juarez S, Reche A, Gomez-Outes A, Martinez-Gonzalez J, Fontcuberta J. Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA study. Int J Clin Prac, 2006, 60(5): 518-525.Santamaria A, Juarez S, Reche A, Gomez-Outes A, Martinez-Gonzalez J, Fontcuberta J. Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA study. Int J Clin Prac, 2006, 60(5): 518-525.Lecumberri R, Rosario E, Pacho J, Rocha E. Fixed-dose low-molecular-weight heparin, bemiparin, in the long-term treatment of ve-nous thromboembolism in patients with transient risk factors in standard clinical practice: the FLEBUS study. J Thromb Haemost, 2006, 4: 2504-2508.Lecumberri R, Rosario E, Pacho J, Rocha E. Fixed-dose low-molecular-weight heparin, bemiparin, in the long-term treatment of ve-nous thromboembolism in patients with transient risk factors in standard clinical practice: the FLEBUS study. J Thromb Haemost, 2006, 4: 2504-2508.Constans M, Santamaria A, Mateo J, Pujol N, Souto JC, Fontcuberta J. Low-molecular-weight heparin as bridging therapy during in-terruption of oral anticoagulation in patients undergoing colonoscopy or gastroscopy. Int J Clin Pract, 2007, 61: 212-217.Constans M, Santamaria A, Mateo J, Pujol N, Souto JC, Fontcuberta J. Low-molecular-weight heparin as bridging therapy during in-terruption of oral anticoagulation in patients undergoing colonoscopy or gastroscopy. Int J Clin Pract, 2007, 61: 212-217.Alalaf SK, Jawad AK, Jawad RK, Ali MS, Al Tawil NG.Bemiparin for thromboprophylaxis after benign gynecologic surgery: a randomized clinical trial. J Thromb Haemost, 2015 Dec, 13(12): 2161-7.Alalaf SK, Jawad AK, Jawad RK, Ali MS, Al Tawil NG.Bemiparin for thromboprophylaxis after benign gynecologic surgery: a randomized clinical trial. J Thromb Haemost, 2015 Dec, 13(12): 2161-7.Ciccone MM, Cortese F, Corbo F, Corrales NE, Al-Momen AK, Silva A, Zito A, Pinto M, Gesualdo M, Scicchitano P. Bemiparin, an effective and safe low molecular weight heparin: a review. Vascul Pharmacol, 2014 Jul, 62(1): 32-7.Ciccone MM, Cortese F, Corbo F, Corrales NE, Al-Momen AK, Silva A, Zito A, Pinto M, Gesualdo M, Scicchitano P. Bemiparin, an effective and safe low molecular weight heparin: a review. Vascul Pharmacol, 2014 Jul, 62(1): 32-7.Monreal Bosch M, Vignoli A, Lecumberri Villamediana R, Prandoni P. Bemiparin in oncology. Drugs, 2010 Dec 14, 70(Suppl 2): 35-42.Monreal Bosch M, Vignoli A, Lecumberri Villamediana R, Prandoni P. Bemiparin in oncology. Drugs, 2010 Dec 14, 70(Suppl 2): 35-42.Abad Rico JI, Lozano S3nchez FS, Rocha E. Clinical experience with bemiparin. Drugs, 2010 Dec 14, 70(Suppl 2): 25-33.Abad Rico JI, Lozano S3nchez FS, Rocha E. Clinical experience with bemiparin. Drugs, 2010 Dec 14, 70(Suppl 2): 25-33.

The authors declare that there are no conflicts of interest present.